Pfenex to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
September 21, 2018 16:29 ET
|
Pfenex, Inc.
SAN DIEGO, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will be presenting at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York. ...
Pfenex Names Dr. Shawn A. Scranton as Sr. Vice President and Chief Operating Officer
September 11, 2018 08:00 ET
|
Pfenex, Inc.
SAN DIEGO, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that Dr. Shawn A. Scranton, will be joining Pfenex as its Chief Operating Officer, effective October...
Pfenex to Present at the Liolios 7th Annual Gateway Conference
September 04, 2018 08:00 ET
|
Pfenex, Inc.
SAN DIEGO, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will be presenting at the Liolios 7th Annual Gateway Conference in San Francisco, CA. ...
Pfenex Announces Departure of Chief Medical and Scientific Officer Dr. Hubert Chen
August 16, 2018 16:05 ET
|
Pfenex, Inc.
SAN DIEGO, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that Dr. Hubert Chen has resigned from his role as Chief Medical and Scientific Officer, effective...
Pfenex Reports Second Quarter Results and Provides Business Update
August 08, 2018 16:05 ET
|
Pfenex, Inc.
SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
Pfenex to Host Conference Call and Webcast Reporting Second Quarter Financial Results on Wednesday, August 8
July 25, 2018 16:05 ET
|
Pfenex, Inc.
SAN DIEGO, July 25, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE AMERICAN:PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology®...
Pfenex Receives Milestone From Merck Associated With Clinical Advancement of Investigational 15-valent Pneumococcal Vaccine PCV-15 (V114)
July 12, 2018 08:00 ET
|
Pfenex, Inc.
SAN DIEGO, July 12, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE AMERICAN:PFNX) today announced the receipt of a milestone payment from Merck associated with the initiation of the first Phase 3...
Pfenex Set to Join Russell 2000® Index
June 22, 2018 17:00 ET
|
Pfenex, Inc.
SAN DIEGO, June 22, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American:PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression...
Pfenex to Present at the JMP Securities 2018 Life Science Conference
June 14, 2018 16:15 ET
|
Pfenex, Inc.
SAN DIEGO, June 14, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American:PFNX) announced today that it will be presenting at the JMP Securities 2018 Life Science Conference in New York City. ...
Pfenex and Alvogen Enter into U.S. Agreement for Commercialization of PF708, a Therapeutic Equivalent Candidate to Forteo®
June 11, 2018 16:05 ET
|
Pfenex, Inc.
SAN DIEGO, June 11, 2018 (GLOBE NEWSWIRE) -- Pfenex (NYSE American:PFNX) and Alvogen today announced entering into an agreement granting Alvogen exclusive rights to commercialize Pfenex’s lead drug...